Compare TEVA & ES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TEVA | ES |
|---|---|---|
| Founded | 1901 | 1927 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.2B | 27.7B |
| IPO Year | N/A | N/A |
| Metric | TEVA | ES |
|---|---|---|
| Price | $28.43 | $66.62 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 12 |
| Target Price | $27.00 | ★ $70.17 |
| AVG Volume (30 Days) | ★ 11.4M | 3.1M |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | N/A | ★ 4.51% |
| EPS Growth | N/A | N/A |
| EPS | 0.62 | ★ 3.65 |
| Revenue | ★ $16,776,000,000.00 | $13,148,536,000.00 |
| Revenue This Year | $4.74 | $10.24 |
| Revenue Next Year | $0.48 | $4.17 |
| P/E Ratio | $46.12 | ★ $18.31 |
| Revenue Growth | 0.02 | ★ 13.12 |
| 52 Week Low | $12.47 | $52.28 |
| 52 Week High | $28.68 | $75.25 |
| Indicator | TEVA | ES |
|---|---|---|
| Relative Strength Index (RSI) | 80.93 | 40.20 |
| Support Level | $24.01 | $65.37 |
| Resistance Level | $26.96 | $67.43 |
| Average True Range (ATR) | 0.68 | 1.58 |
| MACD | 0.19 | -0.14 |
| Stochastic Oscillator | 94.65 | 28.29 |
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Eversource Energy is a diversified holding company with subsidiaries that provide rate-regulated electric and gas distribution service to more than 4 million customers in the Northeast US. Eversource expanded its service territories with acquisitions of NStar (2012), Aquarion (2017), and Columbia Gas (2020). In 2024 Eversource exited its 50% partnership with European utility Orsted to develop 2 gigawatts of offshore wind projects in the Northeast US. The company exited most of its unregulated businesses in 2006.